Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890585 | 1.00 | GRM5 (0.37) | GRM5HRH3CNR2SCD5NTRK1 | |
| SCHEMBL2897993 | 0.90 | SMN1; SMN2 (0.41) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2897988 | 0.90 | SMN1; SMN2 (0.41) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2890592 | 0.86 | GRM5 (0.38) | GRM5CNR2SCD5HCRTR1HCRTR2 | |
| SCHEMBL2890586 | 0.86 | GRM5 (0.38) | GRM5CNR2SCD5HCRTR1HCRTR2 | |
| SCHEMBL2896447 | 0.83 | GRM5 (0.44) | GRM5CNR2SCD5HCRTR1HCRTR2 | |
| SCHEMBL2896453 | 0.83 | GRM5 (0.44) | GRM5CNR2SCD5HCRTR1HCRTR2 | |
| SCHEMBL2898874 | 0.82 | GRM5 (0.46) | GRM5HRH3CNR2HCRTR1HCRTR2 | |
| SCHEMBL2898886 | 0.82 | GRM5 (0.46) | GRM5HRH3CNR2HCRTR1HCRTR2 | |
| SCHEMBL2899532 | 0.78 | GRM5 (0.42) | GRM5HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | GRM5 1/4885HRH3 362/4885CNR2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.